319 related articles for article (PubMed ID: 36535825)
1. A broad assessment of covid-19 vaccine safety using tree-based data-mining in the vaccine safety datalink.
Yih WK; Daley MF; Duffy J; Fireman B; McClure D; Nelson J; Qian L; Smith N; Vazquez-Benitez G; Weintraub E; Williams JTB; Xu S; Maro JC
Vaccine; 2023 Jan; 41(3):826-835. PubMed ID: 36535825
[TBL] [Abstract][Full Text] [Related]
2. Tree-based data mining for safety assessment of first COVID-19 booster doses in the Vaccine Safety Datalink.
Katherine Yih W; Daley MF; Duffy J; Fireman B; McClure D; Nelson J; Qian L; Smith N; Vazquez-Benitez G; Weintraub E; Williams JTB; Xu S; Maro JC
Vaccine; 2023 Jan; 41(2):460-466. PubMed ID: 36481108
[TBL] [Abstract][Full Text] [Related]
3. Safety signal identification for COVID-19 bivalent booster vaccination using tree-based scan statistics in the Vaccine Safety Datalink.
Katherine Yih W; Daley MF; Duffy J; Fireman B; McClure DL; Nelson JC; Qian L; Smith N; Vazquez-Benitez G; Weintraub E; Williams JTB; Xu S; Maro JC
Vaccine; 2023 Aug; 41(36):5265-5270. PubMed ID: 37479610
[TBL] [Abstract][Full Text] [Related]
4. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices - United States, July 2021.
Rosenblum HG; Hadler SC; Moulia D; Shimabukuro TT; Su JR; Tepper NK; Ess KC; Woo EJ; Mba-Jonas A; Alimchandani M; Nair N; Klein NP; Hanson KE; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Mbaeyi SA; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(32):1094-1099. PubMed ID: 34383735
[TBL] [Abstract][Full Text] [Related]
5. Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community.
Abukhalil AD; Shatat SS; Abushehadeh RR; Al-Shami N; Naseef HA; Rabba A
BMC Infect Dis; 2023 Jan; 23(1):5. PubMed ID: 36604613
[TBL] [Abstract][Full Text] [Related]
6. Risk of myopericarditis following COVID-19 mRNA vaccination in a large integrated health system: A comparison of completeness and timeliness of two methods.
Sharff KA; Dancoes DM; Longueil JL; Johnson ES; Lewis PF
Pharmacoepidemiol Drug Saf; 2022 Aug; 31(8):921-925. PubMed ID: 35404496
[TBL] [Abstract][Full Text] [Related]
7. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
[TBL] [Abstract][Full Text] [Related]
8. Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.
Gargano JW; Wallace M; Hadler SC; Langley G; Su JR; Oster ME; Broder KR; Gee J; Weintraub E; Shimabukuro T; Scobie HM; Moulia D; Markowitz LE; Wharton M; McNally VV; Romero JR; Talbot HK; Lee GM; Daley MF; Oliver SE
MMWR Morb Mortal Wkly Rep; 2021 Jul; 70(27):977-982. PubMed ID: 34237049
[TBL] [Abstract][Full Text] [Related]
9. Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
Pillay J; Gaudet L; Wingert A; Bialy L; Mackie AS; Paterson DI; Hartling L
BMJ; 2022 Jul; 378():e069445. PubMed ID: 35830976
[TBL] [Abstract][Full Text] [Related]
10. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021.
Self WH; Tenforde MW; Rhoads JP; Gaglani M; Ginde AA; Douin DJ; Olson SM; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Rivas C; Babcock HM; Kwon JH; Exline MC; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Mills L; Lester SN; Stumpf MM; Naioti EA; Kobayashi M; Verani JR; Thornburg NJ; Patel MM;
MMWR Morb Mortal Wkly Rep; 2021 Sep; 70(38):1337-1343. PubMed ID: 34555004
[TBL] [Abstract][Full Text] [Related]
11. Reactions following Pfizer-BioNTech COVID-19 mRNA vaccination and related healthcare encounters among 7,077 children aged 5-11 years within an integrated healthcare system.
Malden DE; Gee J; Glenn S; Li Z; Mercado C; Ogun OA; Kim S; Lewin BJ; Ackerson BK; Jazwa A; Weintraub ES; McNeil MM; Tartof SY
Vaccine; 2023 Jan; 41(2):315-322. PubMed ID: 36351861
[TBL] [Abstract][Full Text] [Related]
12. Myocarditis and/or pericarditis risk after mRNA COVID-19 vaccination: A Canadian head to head comparison of BNT162b2 and mRNA-1273 vaccines.
Abraham N; Spruin S; Rossi T; Fireman B; Zafack J; Blaser C; Shaw A; Hutchings K; Ogunnaike-Cooke S
Vaccine; 2022 Jul; 40(32):4663-4671. PubMed ID: 35750537
[TBL] [Abstract][Full Text] [Related]
13. Epidemiology of Myocarditis and Pericarditis Following mRNA Vaccination by Vaccine Product, Schedule, and Interdose Interval Among Adolescents and Adults in Ontario, Canada.
Buchan SA; Seo CY; Johnson C; Alley S; Kwong JC; Nasreen S; Calzavara A; Lu D; Harris TM; Yu K; Wilson SE
JAMA Netw Open; 2022 Jun; 5(6):e2218505. PubMed ID: 35749115
[TBL] [Abstract][Full Text] [Related]
14. Determinants of COVID-19 vaccine-induced myocarditis.
Rose J; Hulscher N; McCullough PA
Ther Adv Drug Saf; 2024; 15():20420986241226566. PubMed ID: 38293564
[TBL] [Abstract][Full Text] [Related]
15. COVID-19 Vaccine Safety in Adolescents Aged 12-17 Years - United States, December 14, 2020-July 16, 2021.
Hause AM; Gee J; Baggs J; Abara WE; Marquez P; Thompson D; Su JR; Licata C; Rosenblum HG; Myers TR; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(31):1053-1058. PubMed ID: 34351881
[TBL] [Abstract][Full Text] [Related]
16. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.
Hause AM; Marquez P; Zhang B; Su JR; Myers TR; Gee J; Panchanathan SS; Thompson D; Shimabukuro TT; Shay DK
MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(2):39-43. PubMed ID: 36634021
[TBL] [Abstract][Full Text] [Related]
17. Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types.
Li M; Yuan J; Lv G; Brown J; Jiang X; Lu ZK
J Pers Med; 2021 Oct; 11(11):. PubMed ID: 34834458
[TBL] [Abstract][Full Text] [Related]
18. Incidence Rates and Clinical Characteristics of Patients With Confirmed Myocarditis or Pericarditis Following COVID-19 mRNA Vaccination: Experience of the Veterans Health Administration Through 9 October 2022.
Luo J; Hur K; Salone C; Huang N; Burk M; Pandey L; Thakkar B; Donahue M; Cunningham F
Open Forum Infect Dis; 2023 Jul; 10(7):ofad268. PubMed ID: 37469619
[TBL] [Abstract][Full Text] [Related]
19. A review of COVID-19 vaccination and the reported cardiac manifestations.
Ho JSY; Sia CH; Ngiam JN; Loh PH; Chew NWS; Kong WK; Poh KK
Singapore Med J; 2023 Sep; 64(9):543-549. PubMed ID: 34808708
[TBL] [Abstract][Full Text] [Related]
20. Management of cardiovascular symptoms after Pfizer-BioNTech COVID-19 vaccine in teenagers in the emergency department.
Liao YF; Tseng WC; Wang JK; Chen YS; Chen CA; Lin MT; Lu CW; Wu MH; Chiu SN
J Formos Med Assoc; 2023 Aug; 122(8):699-706. PubMed ID: 36564302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]